The 2019 Mundipharma ANZUP Uro-Oncology Clinical Research Fellowship has been awarded to medical oncologist and clinical research fellow Doctor Angelyn Anton, providing $60,000 to support her research into prostate cancer.
This is the sixth annual Clinical Research Fellowship to be awarded in partnership with the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) to support genitourinary cancer research.
The Fellowship was previously awarded by Tolmar Australia, which was acquired by Mundipharma in 2018, along with exclusive Australian and New Zealand distribution rights for two prostate cancer medications.
Dr Anton was announced as the recipient of the Fellowship surrounded by experts in the research and treatment of genitourinary cancers at the 2019 ANZUP Annual Scientific Meeting in Brisbane.
“Mundipharma is proud to continue this support for research that will result in real improvements in the treatment and management of prostate cancer,” said Jane Orr, Managing Director of Mundipharma Australia and New Zealand.
“I am delighted to continue Mundipharma’s partnership with ANZUP to offer this Fellowship, which again attracted many impressive applications from ANZUP’s multidisciplinary membership across Australia and from a range of institutions and professional groups.”
“Dr Anton has a remarkable drive to help improve clinical practice and this Fellowship will help her reach that potential.”
ANZUP Chair Professor Ian Davis said Dr Anton was very deserving of this recognition.
“The Mundipharma ANZUP Uro-oncology Clinical Research Fellowship has supported some of Australia’s best and brightest emerging clinician-researchers, and Dr Anton is the latest addition to that eminent group,” Professor Davis said.
“She has already proven her capability and submitted a very competitive application that stood out amongst many other excellent applicants. ANZUP is glad to be able to provide this Fellowship to her, with the generous support of Mundipharma.”
The Fellowship is intended for early and mid-career clinician-researchers of any health care discipline in genitourinary cancer research and provides funding for one year to the institution of the successful applicant.
“Dr Anton’s research is focussed on comparing rates of cognitive decline in elderly prostate cancer patients receiving novel antiandrogens,” Ms Orr said.
“This research will provide relevant and valuable data to inform future decision making, influence current clinical practice and ultimately improve patient outcomes.”
Dr Anton said her research primarily involved the use of real world data to examine current treatment patterns and outcomes in prostate cancer.
“The Mundipharma ANZUP Uro-Oncology Clinical Research Fellowship has provided a significant opportunity to further my clinical research goals and to support the REAL-Pro study, the first prospective registry-based randomised clinical trial in prostate cancer,” Dr Anton said.
Prostate cancer is the most commonly diagnosed cancer in Australian males, with one in six men expected to be diagnosed before the age of 85. It is also the third most common cause of cancer death.